Known targets — ChEMBL curated mechanism
ABCC9ABL1ACEACHEACVR1ADORA1ADORA2AADORA2BADORA3ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALOX5ATP4AATP4BBCRBTKCACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGCRBNCUL4ACXCR1CXCR2DDB1DDCDHFRDPP4DRD2DRD3DRD4EGFRERBB2ERBB4ESR1ESR2FDPSFKBP1AFLT1FLT3FLT4GARTGHSRGRIA1GRIA2GRIA3GRIA4GRIK1GRIK2GRIK3GRIK4GRIK5GRIN2AGSK3AGSK3BHDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IDH1IDH2IMPA1ITGA2BITGB3JAK1JAK2JAK3KCNJ11KCNK3KCNK9KDRKITMEN1METMMP1MMP13MMP7MMP8NANOD2NS5bODC1OPG057OPRD1OPRK1OPRM1PPARP1PARP2PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PKLRPPARDPPATPTGS1PTGS2RBX1ROCK1ROCK2RRM1RRM2RRM2BSCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC10A2SLC5A2SLC6A2SLC6A3SLC6A4SLC9A3SYKTACR1THRATHRBTOP1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYK2TYMSVDRampCblablaT-3blaT-4blaT-5blaT-6blaUOE-1dacAdacBdacCfolAfolPftsIgyrAgyrBileSmecAmrcAmrcBmrdAparCparEpbp2pbp4pbpApbpFrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUthyAykgMykgO
The experimentally established mechanism targets of Water. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 known ✓ | P35372 | 2/20 | 0.45 |
| ▸ | OPRD1 known ✓ | P41143 | 2/20 | 0.45 |
| ▸ | OPRK1 known ✓ | P41145 | 2/20 | 0.45 |
| ▸ | MMP1 known ✓ | P03956 | 1/20 | 0.44 |
| ▸ | MMP13 known ✓ | P45452 | 1/20 | 0.44 |
| ▸ | CNR2 | P34972 | 1/20 | 0.58 |
| ▸ | TSHR | P16473 | 4/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.57 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.52 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.50 |
| ▸ | CALM1 | P0DP23 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.44 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.44 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | MGLL | Q99685 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL134524 | 0.97 | TSHR (0.60) | CNR2TSHRALDH1A1AOC3TRPA1 | |
| Bromide SCHEMBL6760453 | 0.94 | CNR2 (0.58) | CNR2TSHRALDH1A1AOC3TRPA1 | |
| Fluoride SCHEMBL633879 | 0.94 | CNR2 (0.58) | CNR2TSHRALDH1A1AOC3TRPA1 | |
| Hydrochloric Acid SCHEMBL2137949 | 0.94 | CNR2 (0.58) | CNR2TSHRALDH1A1AOC3TRPA1 | |
| SCHEMBL12049793 | 0.94 | CNR2 (0.64) | CNR2TSHRALDH1A1AOC3TRPA1 | |
| Ammonia Solution, Strong SCHEMBL1348044 | 0.94 | CNR2 (0.58) | CNR2TSHRALDH1A1AOC3TRPA1 | |
| Bromide SCHEMBL11212819 | 0.94 | CNR2 (0.58) | CNR2TSHRALDH1A1AOC3TRPA1 | |
| Chloromethane SCHEMBL27571631 | 0.88 | CNR2 (0.59) | CNR2TSHRALDH1A1AOC3TRPA1 | |
| SCHEMBL11326900 | 0.87 | CNR2 (0.48) | CNR2TSHRALDH1A1AOC3TRPA1 | |
| Tetramethylammonium Ion SCHEMBL9770085 | 0.86 | CNR2 (0.57) | CNR2TSHRALDH1A1AOC3TRPA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 98 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106145155-B | A kind of method preparing high silica alumina ratio Y type molecular sieve, product and its application | 中国科学院大连化学物理研究所 | 2019-02-15 | — | — | CN | claimed |
| CN-106145155-A | A kind of prepare the method for high silica alumina ratio Y type molecular sieve, product and application thereof | 中国科学院大连化学物理研究所 | 2016-11-23 | — | — | CN | claimed |
| CN-108885412-A | Processing liquid for semiconductor manufacturing and pattern forming method | 富士胶片株式会社 | 2018-11-23 | — | — | CN | disclosed |
| CN-106145155-A | A kind of prepare the method for high silica alumina ratio Y type molecular sieve, product and application thereof | 中国科学院大连化学物理研究所 | 2016-11-23 | — | — | CN | disclosed |
| EP-1658846-B1 | N-(8,8,8-trifluorooctyl)-1,5-dideoxy-1,5-imino-D-glucitol for treating hepatitis virus infections | UNITED THERAPEUTICS CORP (US) | 2008-07-30 | — | — | EP | disclosed |
| US-20060264468-A1 | Use of substituted-1, 5-dideoxy-1, 5-imino-D-glucitol compounds for treating hepatitis virus infections | UNITED THERAPEUTICS CORPORATION | 2006-11-23 | — | — | US | disclosed |
| US-7115632-B1 | Sulfonyl aryl or heteroaryl hydroxamic acid compounds | G. D. SEARLE & CO. (US) | 2006-10-03 | — | — | US | disclosed |
| EP-1658846-A1 | Substituted-1,5-dideoxy-1,5-imino-D-glucitol compounds for treating hepatitis virus infections | G.D. SEARLE & CO. (US) | 2006-05-24 | — | — | EP | disclosed |
| US-20060084688-A1 | Aromatic sulfone hydroxamic acid metalloprotease inhibitor | BARTA THOMAS E | 2006-04-20 | — | — | US | disclosed |
| US-6890937-B2 | Aromatic sulfone hydroxamic acid metalloprotease inhibitor | PHARMACIA CORPORATION (US) | 2005-05-10 | — | — | US | disclosed |
| US-20050075374-A1 | Sulfonyl aryl or heteroaryl hydroxamic acid compounds | PHARMACIA CORPORATION | 2005-04-07 | — | — | US | disclosed |
| WO-1998039326-A1 | AROMATIC SULFONYL ALPHA-HYDROXY HYDROXAMIC ACID COMPOUNDS | MONSANTO COMPANY (US) | 1998-09-11 | — | — | WO | disclosed |
| WO-1998039316-A1 | N-HYDROXY 4-SULFONYL BUTANAMIDE COMPOUNDS | MONSANTO COMPANY (US) | 1998-09-11 | — | — | WO | disclosed |
| WO-1998039315-A1 | AROMATIC SULFONYL ALPHA-CYCLOAMINO HYDROXAMIC ACID COMPOUNDS | MONSANTO COMPANY (US) | 1998-09-11 | — | — | WO | disclosed |
| WO-1998039313-A1 | THIOARYL SULFONAMIDE HYDROXAMIC ACID COMPOUNDS | MONSANTO COMPANY (US) | 1998-09-11 | — | — | WO | disclosed |
| WO-1998038859-A1 | SULFONYL DIVALENT ARYL OR HETEROARYL HYDROXAMIC ACID COMPOUNDS | MONSANTO COMPANY (US) | 1998-09-11 | — | — | WO | disclosed |
| WO-1998039329-A1 | AMIDOAROMATIC RING SULFONAMIDE HYDROXAMIC ACID COMPOUNDS | MONSANTO COMPANY (US) | 1998-09-11 | — | — | WO | disclosed |
| WO-1998003164-A1 | THIOL SULFONE METALLOPROTEASE INHIBITORS | MONSANTO COMPANY (US) | 1998-01-29 | — | — | WO | disclosed |
| WO-1998003166-A1 | THIOL SULFONAMIDE METALLOPROTEASE INHIBITORS | MONSANTO COMPANY (US) | 1998-01-29 | — | — | WO | disclosed |
| US-3995998-A | Method of polymerizing and fixing carboxyl-containing vinyl monomers in high conversion on fibrous substrates | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF AGRICULTURE (US) | 1976-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050075374-A1 | Sulfonyl aryl or heteroaryl hydroxamic acid compounds | MMP1, MMP2, MMP3 | OPRM1 4091/4885OPRD1 4492/4885OPRK1 3999/4885 |
| US-20060264468-A1 | Use of substituted-1, 5-dideoxy-1, 5-imino-D-glucitol compounds for treating hepatitis virus infections | IMPDH1, HAVCR2, DERA | OPRM1 3004/4885OPRD1 1935/4885OPRK1 2807/4885 |
| US-20060084688-A1 | Aromatic sulfone hydroxamic acid metalloprotease inhibitor | MMP13, MMP9, MMP3 | OPRM1 1396/4885OPRD1 1775/4885OPRK1 1997/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.